Tom Wilbur Tom Wilbur is a director of public affairs at PhRMA focusing on the organization’s federal advocacy priorities including intellectual property and Medicare Part D. Prior to joining PhRMA, Tom worked in national and state politics for nearly a decade, most recently on Capitol Hill as a strategic communicator and campaign manager. Tom is a proud Michigander and in his spare time enjoys reading, live music, and spending time with friends and family cheering on Detroit sports teams.
Recent Posts
IP Explained: Four things to know about the Bayh-Dole Act
By Tom Wilbur | September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...
Read More
IP Explained: Three forms of IP protections for medicines
By Tom Wilbur | August 27, 2019
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...
Read More
Three reasons the Senate Finance package is the wrong approach for patients
By Tom Wilbur | August 26, 2019
For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept...
Read More
Four Things You Should Know About AARP
By Tom Wilbur | August 14, 2019
As lawmakers in Washington consider policies to make changes to Medicare prescription drug coverage, one solution that would provide immediate relief is sharing the savings biopharmaceutical...
Read More
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
By Tom Wilbur | August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...
Read More
IP Explained: Why IP protections are important for biologic medicines
By Tom Wilbur | July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
The Department of Health and Human Services recently proposed a rule that would encourage using discounts negotiated between biopharmaceutical manufacturers and Part D plans to reduce patients’...
Read More
What you need to know about the CBO rebate rule score
By Tom Wilbur | May 23, 2019
Earlier this year, the Department of Health & Human Services (HHS) Office of Inspector General (OIG) released a proposed rule that takes aim at today’s complex system of list prices and rebates in...
Read More
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
By Tom Wilbur | May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
